Diversifying the vaccine development pipeline has been recognized as a priority in the Global TB Vaccine R&D Roadmap. The TBVAC-HORIZON consortium has successfully secured funding for an ambitious four-year project that aims to fill the early stages of the development pipeline while ensuring a diverse portfolio of vaccine candidates (TBVAC-HORIZON – TBVI).
One of the key objectives of this project is to conduct head-to-head comparisons of new candidate TB vaccines, both within the TBVAC-HORIZON consortium and beyond.
We are pleased to announce our fourth call for applications. This call offers a unique opportunity to assess the efficacy of your pre-clinical TB vaccine candidate using head-to-head comparison animal models available within the TBVAC-Horizon project consortium.
There are four separate models available: a mouse aerosol challenge model (Annex Ia), a mouse TB meningitis model (Annex Ib), and a low dose (Annex Ic), and ultra-low dose (Annex Id) guinea pig challenge model.
The choice of model will be determined by the stage of the vaccine development, current preclinical data and evidence need for further candidate development. This is part of a gating and prioritisation process to identify new candidates to add to and diversify the preclinical vaccine pipeline (www.tbvacpathway.com ).
Details on the experimental setup and the parameters that are routinely assessed are described in the annexes Ia-Id. The criteria and selection process for evaluation of submissions are described in Annex II.
We invite anyone with a candidate in a relevant stage of development to seize this chance and submit their vaccine candidate for testing. If you do not have a candidate yourself, but know someone who does, please share this opportunity with them.
How to Apply:
Using the Application form (Annex III), provide a 4-page scientific background with relevant referencing to address the criteria (Annex II) on the vaccine/adjuvant/delivery route and delivery system.
Deadline to apply:
Send the completed application form to info@tbvi.eu 31 March 2026 at the latest.
Outcome
All applicants will receive an email on the selection outcome of their submitted candidate by 6 May 2026 at the latest. The successful applicants will be contacted with further information.
For more information and to apply, please check the Application form, along with supporting information and guidance for the application.
TBVAC-HORIZON receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101080309. It is funded by the European Union, the UK Research and Innovation, and the Swiss State Secretariat for Education, Research and Innovation. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union, UKRI, SERI nor the granting authority can be held responsible for them.